232 related articles for article (PubMed ID: 22124153)
1. The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.
Singh PK; Singh S; Ganesh S
Mol Cell Biol; 2012 Feb; 32(3):652-63. PubMed ID: 22124153
[TBL] [Abstract][Full Text] [Related]
2. Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.
Upadhyay M; Gupta S; Bhadauriya P; Ganesh S
Biochem Biophys Res Commun; 2015 Aug; 464(1):106-11. PubMed ID: 26102034
[TBL] [Abstract][Full Text] [Related]
3. Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.
Mittal S; Upadhyay M; Singh PK; Parihar R; Ganesh S
J Biosci; 2015 Dec; 40(5):863-71. PubMed ID: 26648032
[TBL] [Abstract][Full Text] [Related]
4. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment.
Mittal S; Dubey D; Yamakawa K; Ganesh S
Hum Mol Genet; 2007 Apr; 16(7):753-62. PubMed ID: 17337485
[TBL] [Abstract][Full Text] [Related]
5. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway.
Solaz-Fuster MC; Gimeno-Alcañiz JV; Ros S; Fernandez-Sanchez ME; Garcia-Fojeda B; Criado Garcia O; Vilchez D; Dominguez J; Garcia-Rocha M; Sanchez-Piris M; Aguado C; Knecht E; Serratosa J; Guinovart JJ; Sanz P; Rodriguez de Córdoba S
Hum Mol Genet; 2008 Mar; 17(5):667-78. PubMed ID: 18029386
[TBL] [Abstract][Full Text] [Related]
6. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
Upadhyay M; Agarwal S; Bhadauriya P; Ganesh S
Neurobiol Dis; 2017 Apr; 100():39-51. PubMed ID: 28063983
[TBL] [Abstract][Full Text] [Related]
7. Activation of serum/glucocorticoid-induced kinase 1 (SGK1) underlies increased glycogen levels, mTOR activation, and autophagy defects in Lafora disease.
Singh PK; Singh S; Ganesh S
Mol Biol Cell; 2013 Dec; 24(24):3776-86. PubMed ID: 24131995
[TBL] [Abstract][Full Text] [Related]
8. Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.
Liu Y; Zeng L; Ma K; Baba O; Zheng P; Liu Y; Wang Y
Mol Neurobiol; 2014 Apr; 49(2):645-57. PubMed ID: 24068615
[TBL] [Abstract][Full Text] [Related]
9. Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease?
Puri R; Ganesh S
Autophagy; 2010 Nov; 6(8):1229-31. PubMed ID: 20818153
[TBL] [Abstract][Full Text] [Related]
10. The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.
Garyali P; Siwach P; Singh PK; Puri R; Mittal S; Sengupta S; Parihar R; Ganesh S
Hum Mol Genet; 2009 Feb; 18(4):688-700. PubMed ID: 19036738
[TBL] [Abstract][Full Text] [Related]
11. Impaired malin expression and interaction with partner proteins in Lafora disease.
Skurat AV; Segvich DM; Contreras CJ; Hu YC; Hurley TD; DePaoli-Roach AA; Roach PJ
J Biol Chem; 2024 May; 300(5):107271. PubMed ID: 38588813
[TBL] [Abstract][Full Text] [Related]
12. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
[TBL] [Abstract][Full Text] [Related]
13. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
[TBL] [Abstract][Full Text] [Related]
14. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
Mitra S; Chen B; Wang P; Chown EE; Dear M; Guisso DR; Mariam U; Wu J; Gumusgoz E; Minassian BA
Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36511140
[TBL] [Abstract][Full Text] [Related]
15. Lafora disease: Current biology and therapeutic approaches.
Mitra S; Gumusgoz E; Minassian BA
Rev Neurol (Paris); 2022 Apr; 178(4):315-325. PubMed ID: 34301405
[TBL] [Abstract][Full Text] [Related]
16. Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Rao SN; Sharma J; Maity R; Jana NR
J Biol Chem; 2010 Jan; 285(2):1404-13. PubMed ID: 19892702
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease.
Sanchez-Martin P; Lahuerta M; Viana R; Knecht E; Sanz P
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118613. PubMed ID: 31758957
[TBL] [Abstract][Full Text] [Related]
18. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
Rai A; Mishra R; Ganesh S
Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665
[TBL] [Abstract][Full Text] [Related]
19. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
[TBL] [Abstract][Full Text] [Related]
20. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
